APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeting p53 Cancer Therapies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Targeting p53 Cancer Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025183 pages

Choose your research edition.

Industry ResearchTargeting p53 Cancer Therapies Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeting p53 Cancer Therapies Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Targeting p53 Cancer Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeting p53 Cancer Therapies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeting p53 Cancer Therapies Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Targeting p53 Cancer Therapies market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Targeting p53 Cancer Therapies include Alieron Therapeutics, Aprea Therapeutics, Kartos Therapeutics, MultiVir, Rain Oncology, SynerGene Therapeutics, Jc (Wuxi) Company, Sibiono GeneTech and Ascentage Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Targeting p53 Cancer Therapies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Targeting p53 Cancer Therapies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Targeting p53 Cancer Therapies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Targeting p53 Cancer Therapies market size, projected growth trends, production technologies, key applications, and end-use industries.

Targeting p53 Cancer Therapies Segment by Company

Alieron Therapeutics

Aprea Therapeutics

Kartos Therapeutics

MultiVir

Rain Oncology

SynerGene Therapeutics

Jc (Wuxi) Company

Sibiono GeneTech

Ascentage Pharma

Targeting p53 Cancer Therapies Segment by Type

Gene Therapy

Immunotherapy

Small Molecule Drugs

Others

Targeting p53 Cancer Therapies Segment by Application

Hospital

Clinic

Others

Targeting p53 Cancer Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeting p53 Cancer Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeting p53 Cancer Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeting p53 Cancer Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Targeting p53 Cancer Therapies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Targeting p53 Cancer Therapies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Targeting p53 Cancer Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Targeting p53 Cancer Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Targeting p53 Cancer Therapies Industry Trends Table 2. Targeting p53 Cancer Therapies Industry Drivers Table 3. Targeting p53 Cancer Therapies Industry Opportunities and Challenges Table 4. Targeting p53 Cancer Therapies Industry Restraints Table 5. Global Targeting p53 Cancer Therapies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Targeting p53 Cancer Therapies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Targeting p53 Cancer Therapies Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Targeting p53 Cancer Therapies Sales Market Share by Manufacturers Table 9. Global Targeting p53 Cancer Therapies Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Targeting p53 Cancer Therapies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Targeting p53 Cancer Therapies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Targeting p53 Cancer Therapies Manufacturers, Product Type & Application Table 13. Global Targeting p53 Cancer Therapies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Targeting p53 Cancer Therapies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Gene Therapy Table 17. Major Manufacturers of Immunotherapy Table 18. Major Manufacturers of Small Molecule Drugs Table 19. Major Manufacturers of Others Table 20. Global Targeting p53 Cancer Therapies Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (k units) Table 22. Global Targeting p53 Cancer Therapies Sales by Type (2027-2032) & (k units) Table 23. Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026) Table 24. Global Targeting p53 Cancer Therapies Sales Market Share by Type (2027-2032) Table 25. Global Targeting p53 Cancer Therapies Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Targeting p53 Cancer Therapies Revenue by Type (2021-2026) & (k units) Table 27. Global Targeting p53 Cancer Therapies Revenue by Type (2027-2032) & (k units) Table 28. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2026) Table 29. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Targeting p53 Cancer Therapies Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (k units) Table 35. Global Targeting p53 Cancer Therapies Sales by Application (2027-2032) & (k units) Table 36. Global Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026) Table 37. Global Targeting p53 Cancer Therapies Sales Market Share by Application (2027-2032) Table 38. Global Targeting p53 Cancer Therapies Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Targeting p53 Cancer Therapies Revenue by Application (2021-2026) & (k units) Table 40. Global Targeting p53 Cancer Therapies Revenue by Application (2027-2032) & (k units) Table 41. Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2026) Table 42. Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2027-2032) Table 43. Global Targeting p53 Cancer Therapies Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Targeting p53 Cancer Therapies Sales by Region (2021-2026) & (k units) Table 45. Global Targeting p53 Cancer Therapies Sales Market Share by Region (2021-2026) Table 46. Global Targeting p53 Cancer Therapies Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Targeting p53 Cancer Therapies Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Targeting p53 Cancer Therapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 50. North America Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units) Table 51. Europe Targeting p53 Cancer Therapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 53. Europe Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Targeting p53 Cancer Therapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Targeting p53 Cancer Therapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units) Table 60. Global Targeting p53 Cancer Therapies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Targeting p53 Cancer Therapies Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Targeting p53 Cancer Therapies Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Targeting p53 Cancer Therapies Revenue Market Share by Region (2021-2026) Table 64. Global Targeting p53 Cancer Therapies Revenue Market Share by Region (2027-2032) Table 65. Alieron Therapeutics Company Information Table 66. Alieron Therapeutics Business Overview Table 67. Alieron Therapeutics Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 69. Alieron Therapeutics Recent Development Table 70. Aprea Therapeutics Company Information Table 71. Aprea Therapeutics Business Overview Table 72. Aprea Therapeutics Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 74. Aprea Therapeutics Recent Development Table 75. Kartos Therapeutics Company Information Table 76. Kartos Therapeutics Business Overview Table 77. Kartos Therapeutics Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 79. Kartos Therapeutics Recent Development Table 80. MultiVir Company Information Table 81. MultiVir Business Overview Table 82. MultiVir Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. MultiVir Targeting p53 Cancer Therapies Product Portfolio Table 84. MultiVir Recent Development Table 85. Rain Oncology Company Information Table 86. Rain Oncology Business Overview Table 87. Rain Oncology Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Rain Oncology Targeting p53 Cancer Therapies Product Portfolio Table 89. Rain Oncology Recent Development Table 90. SynerGene Therapeutics Company Information Table 91. SynerGene Therapeutics Business Overview Table 92. SynerGene Therapeutics Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 94. SynerGene Therapeutics Recent Development Table 95. Jc (Wuxi) Company Company Information Table 96. Jc (Wuxi) Company Business Overview Table 97. Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio Table 99. Jc (Wuxi) Company Recent Development Table 100. Sibiono GeneTech Company Information Table 101. Sibiono GeneTech Business Overview Table 102. Sibiono GeneTech Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio Table 104. Sibiono GeneTech Recent Development Table 105. Ascentage Pharma Company Information Table 106. Ascentage Pharma Business Overview Table 107. Ascentage Pharma Targeting p53 Cancer Therapies Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio Table 109. Ascentage Pharma Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Targeting p53 Cancer Therapies Distributors List Table 113. Targeting p53 Cancer Therapies Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Targeting p53 Cancer Therapies Product Image Figure 2. Global Targeting p53 Cancer Therapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeting p53 Cancer Therapies Market Size (2021-2032) & (US$ Million) Figure 4. Global Targeting p53 Cancer Therapies Sales (2021-2032) & (k units) Figure 5. Global Targeting p53 Cancer Therapies Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Targeting p53 Cancer Therapies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Gene Therapy Image Figure 9. Immunotherapy Image Figure 10. Small Molecule Drugs Image Figure 11. Others Image Figure 12. Global Targeting p53 Cancer Therapies Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Targeting p53 Cancer Therapies Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2032) Figure 15. Global Targeting p53 Cancer Therapies Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Targeting p53 Cancer Therapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Targeting p53 Cancer Therapies Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Targeting p53 Cancer Therapies Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2032) Figure 24. Global Targeting p53 Cancer Therapies Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Targeting p53 Cancer Therapies Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2032) Figure 27. North America Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032) Figure 29. U.S. Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032) Figure 34. Germany Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032) Figure 41. China Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2032) Figure 49. Brazil Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Targeting p53 Cancer Therapies Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Targeting p53 Cancer Therapies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Targeting p53 Cancer Therapies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Targeting p53 Cancer Therapies Revenue (2021-2032) & (US$ Million) Figure 60. North America Targeting p53 Cancer Therapies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Targeting p53 Cancer Therapies Revenue (2021-2032) & (US$ Million) Figure 62. Europe Targeting p53 Cancer Therapies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Targeting p53 Cancer Therapies Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Targeting p53 Cancer Therapies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Targeting p53 Cancer Therapies Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Targeting p53 Cancer Therapies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Targeting p53 Cancer Therapies Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Targeting p53 Cancer Therapies Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Gene Therapy
  • Immunotherapy
  • Small Molecule Drugs
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Alieron Therapeutics
  • Aprea Therapeutics
  • Kartos Therapeutics
  • MultiVir
  • Rain Oncology
  • SynerGene Therapeutics
  • Jc (Wuxi) Company
  • Sibiono GeneTech
  • Ascentage Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Targeting p53 Cancer Therapies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Targeting p53 Cancer Therapies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Targeting p53 Cancer Therapies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Targeting p53 Cancer Therapies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Targeting p53 Cancer Therapies Market Dynamics
  1. 2.1 Targeting p53 Cancer Therapies Industry Trends
  2. 2.2 Targeting p53 Cancer Therapies Industry Drivers
  3. 2.3 Targeting p53 Cancer Therapies Industry Opportunities and Challenges
  4. 2.4 Targeting p53 Cancer Therapies Industry Restraints
3 Targeting p53 Cancer Therapies Market by Manufacturers
  1. 3.1 Global Targeting p53 Cancer Therapies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Targeting p53 Cancer Therapies Sales by Manufacturers (2021-2026)
  3. 3.3 Global Targeting p53 Cancer Therapies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Targeting p53 Cancer Therapies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Targeting p53 Cancer Therapies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Targeting p53 Cancer Therapies Manufacturers, Product Type & Application
  7. 3.7 Global Targeting p53 Cancer Therapies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Targeting p53 Cancer Therapies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Targeting p53 Cancer Therapies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Targeting p53 Cancer Therapies Tier 1, Tier 2, and Tier 3
4 Targeting p53 Cancer Therapies Market by Type
  1. 4.1 Targeting p53 Cancer Therapies Type Introduction
  2. 4.1.1 Gene Therapy
  3. 4.1.2 Immunotherapy
  4. 4.1.3 Small Molecule Drugs
  5. 4.1.4 Others
  6. 4.2 Global Targeting p53 Cancer Therapies Sales by Type
  7. 4.2.1 Global Targeting p53 Cancer Therapies Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Targeting p53 Cancer Therapies Sales by Type (2021-2032)
  9. 4.2.3 Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2032)
  10. 4.3 Global Targeting p53 Cancer Therapies Revenue by Type
  11. 4.3.1 Global Targeting p53 Cancer Therapies Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Targeting p53 Cancer Therapies Revenue by Type (2021-2032)
  13. 4.3.3 Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2032)
5 Targeting p53 Cancer Therapies Market by Application
  1. 5.1 Targeting p53 Cancer Therapies Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Targeting p53 Cancer Therapies Sales by Application
  6. 5.2.1 Global Targeting p53 Cancer Therapies Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Targeting p53 Cancer Therapies Sales by Application (2021-2032)
  8. 5.2.3 Global Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2032)
  9. 5.3 Global Targeting p53 Cancer Therapies Revenue by Application
  10. 5.3.1 Global Targeting p53 Cancer Therapies Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Targeting p53 Cancer Therapies Revenue by Application (2021-2032)
  12. 5.3.3 Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2032)
6 Global Targeting p53 Cancer Therapies Sales by Region
  1. 6.1 Global Targeting p53 Cancer Therapies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Targeting p53 Cancer Therapies Sales by Region (2021-2032)
  3. 6.2.1 Global Targeting p53 Cancer Therapies Sales by Region (2021-2026)
  4. 6.2.2 Global Targeting p53 Cancer Therapies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Targeting p53 Cancer Therapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Targeting p53 Cancer Therapies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Targeting p53 Cancer Therapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Targeting p53 Cancer Therapies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Targeting p53 Cancer Therapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Targeting p53 Cancer Therapies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Targeting p53 Cancer Therapies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Targeting p53 Cancer Therapies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Targeting p53 Cancer Therapies Revenue by Region
  1. 7.1 Global Targeting p53 Cancer Therapies Revenue by Region
  2. 7.1.1 Global Targeting p53 Cancer Therapies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Targeting p53 Cancer Therapies Revenue by Region (2021-2026)
  4. 7.1.3 Global Targeting p53 Cancer Therapies Revenue by Region (2027-2032)
  5. 7.1.4 Global Targeting p53 Cancer Therapies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Targeting p53 Cancer Therapies Revenue (2021-2032)
  8. 7.2.2 North America Targeting p53 Cancer Therapies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Targeting p53 Cancer Therapies Revenue (2021-2032)
  11. 7.3.2 Europe Targeting p53 Cancer Therapies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Targeting p53 Cancer Therapies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Targeting p53 Cancer Therapies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Targeting p53 Cancer Therapies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Targeting p53 Cancer Therapies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Alieron Therapeutics
  2. 8.1.1 Alieron Therapeutics Company Information
  3. 8.1.2 Alieron Therapeutics Business Overview
  4. 8.1.3 Alieron Therapeutics Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  6. 8.1.5 Alieron Therapeutics Recent Developments
  7. 8.2 Aprea Therapeutics
  8. 8.2.1 Aprea Therapeutics Company Information
  9. 8.2.2 Aprea Therapeutics Business Overview
  10. 8.2.3 Aprea Therapeutics Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  12. 8.2.5 Aprea Therapeutics Recent Developments
  13. 8.3 Kartos Therapeutics
  14. 8.3.1 Kartos Therapeutics Company Information
  15. 8.3.2 Kartos Therapeutics Business Overview
  16. 8.3.3 Kartos Therapeutics Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  18. 8.3.5 Kartos Therapeutics Recent Developments
  19. 8.4 MultiVir
  20. 8.4.1 MultiVir Company Information
  21. 8.4.2 MultiVir Business Overview
  22. 8.4.3 MultiVir Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MultiVir Targeting p53 Cancer Therapies Product Portfolio
  24. 8.4.5 MultiVir Recent Developments
  25. 8.5 Rain Oncology
  26. 8.5.1 Rain Oncology Company Information
  27. 8.5.2 Rain Oncology Business Overview
  28. 8.5.3 Rain Oncology Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Rain Oncology Targeting p53 Cancer Therapies Product Portfolio
  30. 8.5.5 Rain Oncology Recent Developments
  31. 8.6 SynerGene Therapeutics
  32. 8.6.1 SynerGene Therapeutics Company Information
  33. 8.6.2 SynerGene Therapeutics Business Overview
  34. 8.6.3 SynerGene Therapeutics Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  36. 8.6.5 SynerGene Therapeutics Recent Developments
  37. 8.7 Jc (Wuxi) Company
  38. 8.7.1 Jc (Wuxi) Company Company Information
  39. 8.7.2 Jc (Wuxi) Company Business Overview
  40. 8.7.3 Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio
  42. 8.7.5 Jc (Wuxi) Company Recent Developments
  43. 8.8 Sibiono GeneTech
  44. 8.8.1 Sibiono GeneTech Company Information
  45. 8.8.2 Sibiono GeneTech Business Overview
  46. 8.8.3 Sibiono GeneTech Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio
  48. 8.8.5 Sibiono GeneTech Recent Developments
  49. 8.9 Ascentage Pharma
  50. 8.9.1 Ascentage Pharma Company Information
  51. 8.9.2 Ascentage Pharma Business Overview
  52. 8.9.3 Ascentage Pharma Targeting p53 Cancer Therapies Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio
  54. 8.9.5 Ascentage Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Targeting p53 Cancer Therapies Value Chain Analysis
  2. 9.1.1 Targeting p53 Cancer Therapies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Targeting p53 Cancer Therapies Production Mode & Process
  6. 9.2 Targeting p53 Cancer Therapies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Targeting p53 Cancer Therapies Distributors
  9. 9.2.3 Targeting p53 Cancer Therapies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst